Ready-to-use high protein oral supplement compensates for intradialytic amino acid losses
Alniche Lifesciences has launched a Complipro / Ezepro, high protein supplements for patients with chronic kidney disease (CKD) and critically ill patients.
The product is the first commercial launch after a Memorandum of Understanding between Alniche and Delhi Pharmaceutical Sciences and Research University (DPSRU), to develop innovative formulations in the field of nephrology and critical care.
There is a strong unmet medical need for high protein supplements for patients with chronic kidney disease and critically ill patients.
Protein-energy wasting is a recurrent issue in CKD and is one of the highest risk indicators of mortality in patients with chronic renal failure. Patients can lose up to 13g of amino acids per session of dialysis. Hence, protein supplementation is of high significance in such patients.
Complipro is reportedly the first ready-to-use high protein oral supplement to compensate intradialytic amino acid losses. As per a company release, the product distinguishes itself from existing options by combining the right quantity of proteins with the right quality of high biologic value proteins to compensate losses and maintain a positive balance during each dialysis session.
Ezepro is the other variant of the product designed to address the unmet needs of critically ill patients. Ezepro is aimed at avoiding muscle wasting, boosting immune function, thus early recovery in the critical care patients.
CompliPro and Ezepro have a pleasant taste with coffee flavour and are available in a ready-to-use single dose can of 150 ml for patient convenience.
The launch was in Vigyan Bhavan in the presence of Anil Baijal, Honourable Lieutenant Governor, Govt of NCT.
Speaking at the launch, Girish Arora, Founder & Managing Director, Alniche Lifesciences expressed his gratitude to the Lieutenant Governor, Deputy CM for their presence and blessings. He also thanked Prof. Ramesh K Goyal, Vice-Chancellor, DPSRU and Prof Harvinder Popli, Dean, DPSRU for their encouragement and support.
As part of the collaboration between Alniche Lifesciences and DPSRU, both partners will work together in three broad areas: formulation & development, concept to creation and analysis and standardisation of differentiated novel pharmaceuticals. Alniche also instituted two awards (Jwalant & Vijayin) to recognise young researchers and new start-ups atDPSRU Innovation and Incubation Foundation (DIIF) to bring new products, concepts and technologies to the Indian market.